{"schema_version":"secwatch.filing_event.v1","accession":"0000950142-22-000881","form_type":"8-K","ticker":"VTVT","cik":"0001641489","company_name":"vTv Therapeutics Inc.","filed_at":"2022-03-03T23:59:59+00:00","discovered_at":"2026-05-14T18:04:07.518090+00:00","generated_at":"2026-06-27T02:01:23.933860+00:00","sec_items":["5.02","5.03","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"CEO Deepa Prasad resigns effective March 29, 2022; Richard Nelson appointed Interim CEO","bullets":["Prasad resigns as CEO/President/Board member, will serve as Strategic Advisor for 6 months.","Prasad receives $325,000 bonus, salary continuation for 15 months, retains 624,659 options.","Richard Nelson appointed Acting CEO until March 29 then Interim CEO; enters employment agreement.","Nelson to receive $200k base salary, 100% cash bonus for FY2022, options for 500,000 shares at $0.8060.","Board amended bylaws to allow appointment of Lead Independent Director."],"urls":{"canonical":"https://secwatch.observer/filing/0000950142-22-000881","json":"https://secwatch.observer/filing/0000950142-22-000881.json","markdown":"https://secwatch.observer/filing/0000950142-22-000881.md","text":"https://secwatch.observer/filing/0000950142-22-000881.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1641489/000095014222000881/0000950142-22-000881-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1641489/000095014222000881/eh220231317_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T02:01:23.933860+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2b43986cff","claim":"Deepa Prasad resigned as Chief Executive Officer at vTv Therapeutics Inc..","evidence_excerpt":"On February 27, 2022, Ms. Deepa Prasad notified the Board of Directors (the “Board”) of vTv Therapeutics Inc. (the “Company”) of her decision to resign from her positions as Chief Executive Officer, President and Board member, effective as of March 29, 2022","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1641489/000095014222000881/0000950142-22-000881-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"d943d241a4","claim":"Richard S. Nelson was appointed as Chief Executive Officer at vTv Therapeutics Inc..","evidence_excerpt":"On March 1, 2022, the Board appointed Mr. Richard S. Nelson as Acting Chief Executive Officer until the Effective Date, at which time Mr. Nelson will become Interim Chief Executive Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1641489/000095014222000881/0000950142-22-000881-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}